EUVIMEDEUVIMED entdecken
EditorialKommentar

Optimizing Dosing of Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer: A Reminder That More Is Not Always Better

Hui Jing Hoe iD, Benjamin J Solomon iD

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.23.01768 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Hui Jing Hoe und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

and toxicity for patients with previously treated HER2 mutation-positive NSCLC.Ongoing studies are evaluating T-DXd 5.4 mg/kg once every 3 weeks compared with chemotherapy plus pembrolizumab in the first-line setting for HER2-mutant NSCLC (DESTINY-Lung04) and in combination strategies with immunotherapy and chemotherapy.In these settings, dose optimization and mitigation of toxicities including drug-induced ILD/pneumonitis and other cumulative low-grade toxicities that are impactful for patients will be essential to enable long-term delivery of this effective new class of therapeutics and maximize therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunoconjugatesHumansFemaleTrastuzumabCamptothecinErb-b2 Receptor Tyrosine Kinases

Substanzen

TrastuzumabCamptothecinImmunoconjugatesErb-b2 Receptor Tyrosine Kinasestrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

ORCID-Profile: Hui Jing Hoe, Benjamin J Solomon

Zitieren

APA

Hoe, H. J., & Solomon, B. J. (2023). Optimizing Dosing of Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer: A Reminder That More Is Not Always Better. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01768

Vancouver

Hoe HJ, Solomon BJ. Optimizing Dosing of Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer: A Reminder That More Is Not Always Better. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.01768

BibTeX
@article{Hoe2023,
  author = {Hoe, Hui Jing and Solomon, Benjamin J},
  title = {Optimizing Dosing of Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer: A Reminder That More Is Not Always Better},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.23.01768}
}
Kostenlos starten →